Human data exists or is emerging, but regulatory approval and long-term safety remain unresolved.
Overview
Retatrutide is an investigational 'triple agonist' targeting the GLP-1, GIP, and glucagon receptors. It is still in clinical development and has generated significant interest from early weight-management trial results.
How It's Thought to Work
Simultaneous activity at three metabolic hormone receptors is being studied for effects on appetite, energy expenditure, and glucose control.
What the Research Says
Phase 2 human trial results have been published; larger Phase 3 trials are ongoing. It is not yet approved.
Key studies to start with
From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Frontiers in pharmacology · 2026
PubMedEmerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide
BMJ case reports · 2026 Oct 7
PubMedDetection and Excretion Profile of Retatrutide in Human Plasma and Urine by LC-HRMS: Implications for Antidoping Analysis
Rapid communications in mass spectrometry : RCM · 2026 Dec 15
Regulatory & Legal Status
Investigational — not FDA-approved. Any product sold to consumers as 'retatrutide' is unapproved and unregulated.
Safety Considerations
Long-term human safety is still being established in trials. Not available as an approved medicine. Consult a clinician.